Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Adjuvant Treatment for BRAF+ Stage III Melanoma: A Case Study to Weigh ICI Versus Targeted Therapies
Adjuvant Treatment for BRAF+ Stage III Melanoma: A Case Study to Weigh ICI Versus Targeted Therapies
How Do Brain Metastases Affect Your Choice of Systemic Treatment in a Patient with HR+/HER2-low MBC?
How Do Brain Metastases Affect Your Choice of Systemic Treatment in a Patient with HR+/HER2-low MBC?
Questions and Conundrums: What Is the Future of ADCs in HR+/HER2-Low MBC?
Questions and Conundrums: What Is the Future of ADCs in HR+/HER2-Low MBC?
What is the Future of Adjuvant Therapy for Resectable Melanoma?
What is the Future of Adjuvant Therapy for Resectable Melanoma?
Selection and Sequencing of ADCs in HR+/HER2-Low MBC
Selection and Sequencing of ADCs in HR+/HER2-Low MBC
Optimizing Adjuvant Treatment for Stage IV Melanoma Patients Rendered NED After Surgery
Optimizing Adjuvant Treatment for Stage IV Melanoma Patients Rendered NED After Surgery
Monitoring and Managing Adverse Effects With ADCs in HR+ Breast Cancer: Strategies To Improve Outcomes
Monitoring and Managing Adverse Effects With ADCs in HR+ Breast Cancer: Strategies To Improve Outcomes
Who Is the Best Candidate for Sequencing Sacituzumab Govitecan Before T-DXd in HR+ Breast Cancer?
Who Is the Best Candidate for Sequencing Sacituzumab Govitecan Before T-DXd in HR+ Breast Cancer?
Who Is the Best Candidate for Sequencing Trastuzumab Detruxtecan (T-DXd) First?
Who Is the Best Candidate for Sequencing Trastuzumab Detruxtecan (T-DXd) First?
How Can We Best Manage irAEs During Adjuvant ICIs for Melanoma? A Case-Based Approach
How Can We Best Manage irAEs During Adjuvant ICIs for Melanoma? A Case-Based Approach
What Are the Data for HER2-Targeted ADCs in HR+/HER2-Low Metastatic Breast Cancer?
What Are the Data for HER2-Targeted ADCs in HR+/HER2-Low Metastatic Breast Cancer?
Which Resected Stage II Melanoma Patients Benefit from Adjuvant ICI Therapy?
Which Resected Stage II Melanoma Patients Benefit from Adjuvant ICI Therapy?
What Are the Data for TROP2-Targeted ADCs in HR+/HER2-Positive and HER2-Low MBC?
What Are the Data for TROP2-Targeted ADCs in HR+/HER2-Positive and HER2-Low MBC?
How Do Patient Characteristics Impact Adjuvant Therapy in All Stages of Resectable Melanoma?
How Do Patient Characteristics Impact Adjuvant Therapy in All Stages of Resectable Melanoma?